GGrantIndex
← Leaderboards

Jill P Smith

Pennsylvania State Univ Hershey Med Ctr

Google Scholar ↗PubMed ↗ORCID ↗
$5,480,175
Attributed
$6,380,155
Total exposure
25
Grants
16
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $630.8K · FY2005–25
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,380,155 · 24
FDA$0 · 1

By mechanism

R01$3,991,925 · 4
R21$1,157,216 · 3
R03$512,195 · 3
K24$474,428 · 1
M01$244,391 · 14

Top collaborators

Most similar at Pennsylvania State Univ Hershey Med Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject”

Research focus

Human SubjectClinical ResearchPeptidesMalignant Neoplasm Of PancreasCholecystokininMalignant NeoplasmsCessation Of LifeHuman Therapy EvaluationCancer EtiologyGrantDrug Screening /EvaluationCellsGastrinsResponseCholecystokinin ReceptorPancreasGrowthUnited StatesGrowth FactorResearch PersonnelPancreas NeoplasmsGastrointestinalNeoplastic GrowthReceptor

Grant awards (48)

The CCK-B receptor signaling pathway as a driver of pancreatic cellular plasticity and carcinogenesis$630,773
R01 · FY2025 · CA · contact PI
The CCK-B receptor signaling pathway as a driver of pancreatic cellular plasticity and carcinogenesis$562,784
R01 · FY2024 · CA · contact PI
The CCK-B receptor signaling pathway as a driver of pancreatic cellular plasticity and carcinogenesis$606,404
R01 · FY2023 · CA · contact PI
Phase 1 study to test safety and dose of proglumide as an anti-fibrotic agent$262,453
R21 · FY2020 · CA · contact PI
Phase 1 study to test safety and dose of proglumide as an anti-fibrotic agent$202,928
R21 · FY2019 · CA · contact PI
High fat diet stimulates pancreatic cancer through the actions of Cholecystokinin$169,106
R21 · FY2016 · CA · contact PI
High fat diet stimulates pancreatic cancer through the actions of Cholecystokinin$200,429
R21 · FY2015 · CA · contact PI
The Cholecystokinin-C (CCK-C) Receptor for Early Detection of Pancreatic Cancer$286,900
R01 · FY2010 · CA · contact PI
The Cholecystokinin-C (CCK-C) Receptor for Early Detection of Pancreatic Cancer$286,900
R01 · FY2009 · CA · contact PI
OGF & Gemcitabine: A Novel Treatment for Pancreatic Cancer: Phase I Study$77,550
R03 · FY2009 · CA · contact PI
THE EFFECTS OF NALTREXONE ON ACTIVE CROHN'S DISEASE$38,826
M01 · FY2009 · RR · contact PI
THE EFFICACY OF LOW DOSE NALTREXONE THERAPY IN CHILDREN WITH CROHN'S$16,178
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: OGF & GEMCITABINE: NOVEL TREATMENT FOR PANCREATIC CANCER$9,707
M01 · FY2009 · RR · contact PI
The Cholecystokinin-C (CCK-C) Receptor for Early Detection of Pancreatic Cancer$286,900
R01 · FY2008 · CA · contact PI
Effects of silencing RNAs for gastrin and CCK on human pancreatic cancer$205,100
R21 · FY2008 · CA · contact PI
OGF & Gemcitabine: A Novel Treatment for Pancreatic Cancer: Phase I Study$77,133
R03 · FY2008 · CA · contact PI
THE EFFECTS OF NALTREXONE ON ACTIVE CROHN'S DISEASE$43,410
M01 · FY2008 · RR · contact PI
TREATMENT OF ADVANCED PANCREATIC CANCER WITH OPIOID GROWTH FACTOR PHASE II$12,576
M01 · FY2008 · RR · contact PI
The Cholecystokinin-C (CCK-C) Receptor for Early Detection of Pancreatic Cancer$286,900
R01 · FY2007 · CA · contact PI
Effects of naltrexone on active Crohn's disease$142,252
R03 · FY2007 · DK · contact PI
Effects of silencing RNAs for gastrin and CCK on human pancreatic cancer$117,200
R21 · FY2007 · CA · contact PI
THE EFFECTS OF NALTREXONE ON ACTIVE CROHN'S DISEASE$16,699
M01 · FY2007 · RR · contact PI
TREATMENT OF ADVANCED PANCREATIC CANCER WITH OPIOID GROWTH FACTOR PHASE II$10,891
M01 · FY2007 · RR · contact PI
Effects of naltrexone on active Crohn's disease$141,850
R03 · FY2006 · DK · contact PI
TREATMENT OF ADVANCED PANCREATIC CANCER WITH OPIOID GROWTH FACTOR PHASE II$28,390
M01 · FY2006 · RR · contact PI
EFFICACY OF LOW DOSE NALTREXONE THERAPY IN CROHN'S DISEASE$861
M01 · FY2006 · RR · contact PI
TREATMENT OF ADVANCED PANCREATIC CANCER WITH OPIOID GROWTH FACTOR PHASE II$30,933
M01 · FY2005 · RR
EFFICACY OF LOW DOSE NALTREXONE THERAPY IN CROHN'S DISEASE$27,194
M01 · FY2005 · RR
Treatment of Advanced Pancreatic Cancer with Growth Fac*$0
R01 · FY2005 · FD
GASTROINTESTINAL PEPTIDES AND PANCREATIC CANCER$260,091
R01 · FY2004 · CA
Low Dose Naltrexone Therapy in Crohn's Disease$8,726
M01 · FY2004 · RR
GASTROINTESTINAL PEPTIDES AND PANCREATIC CANCER$264,091
R01 · FY2003 · CA
PEPTIDES AND PANCREATIC CANCER$118,607
K24 · FY2003 · CA
GASTROINTESTINAL PEPTIDES AND PANCREATIC CANCER$260,091
R01 · FY2002 · CA
PEPTIDES AND PANCREATIC CANCER$118,607
K24 · FY2002 · CA
TREATMENT OF HEPATITIS C WITH AMANTADINE: DOSE ESCALATION STUDY$0
M01 · FY2002 · RR
TREATING ADVANCED PANCREATIC CANCER WITH OPIOID GROWTH FACTOR, PHASE I$0
M01 · FY2002 · RR
TREATMENT OF CHRONIC HEPATITIS C WITH AMANTADINE HYDROCHLORIDE$0
M01 · FY2002 · RR
GASTROINTESTINAL PEPTIDES AND PANCREATIC CANCER$260,091
R01 · FY2001 · CA
PEPTIDES AND PANCREATIC CANER$118,607
K24 · FY2001 · CA
TREATMENT OF HEPATITIS C WITH AMANTADINE: DOSE ESCALATION STUDY$0
M01 · FY2001 · RR
TREATING ADVANCED PANCREATIC CANCER WITH OPIOID GROWTH FACTOR, PHASE I$0
M01 · FY2001 · RR
TREATMENT OF CHRONIC HEPATITIS C WITH AMANTADINE HYDROCHLORIDE$0
M01 · FY2001 · RR
PEPTIDES AND PANCREATIC CANER$118,607
K24 · FY2000 · CA
OPIOID GROWTH FACTOR AND PANCREATIC CANCER--PHASE 1$73,410
R03 · FY2000 · CA
TREATMENT OF HEPATITIS C WITH AMANTADINE: DOSE ESCALATION STUDY$0
M01 · FY2000 · RR
TREATING ADVANCED PANCREATIC CANCER WITH OPIOID GROWTH FACTOR, PHASE I$0
M01 · FY2000 · RR
TREATMENT OF CHRONIC HEPATITIS C WITH AMANTADINE HYDROCHLORIDE$0
M01 · FY2000 · RR